Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07403214 · ClinicalTrials.gov registry record
A Real-world Study of Disease-modifying Therapy Treatment Outcomes in Patients With Spinal Muscular Atrophy
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 4,805
- Enrollment target
NCT07403214: Completed study, sponsored by Novartis Pharmaceuticals.
NCT07403214 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 4,805 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07403214 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 4,805 participants
- Enrollment target
Study Summary
The aim of this study was to evaluate treatment patterns, SMA-related complications and services, and all-cause medical encounters of patients with SMA receiving multiple DMTs in the real world. The DMTs included onasemnogene abeparvovec-xioi (OA), nusinersen, and risdiplam. This study was conducted using data from the Komodo Health Research Database (KRD+) between 01 January 2016 and 31 October 2024.
Primary Outcome
DME is medical equipment that assists patients with their medical condition, can be used at home, and lasts a long time.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,805 participants |
| Start Date | 2025-06-04 |
| Est. Completion | 2025-06-30 |
What the finished NCT07403214 record still lists
NCT07403214 is an observational study that tracks outcomes without assigning an intervention. Its 4,805 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT07403214 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07403214 about?
NCT07403214 is a clinical study titled "A Real-world Study of Disease-modifying Therapy Treatment Outcomes in Patients With Spinal Muscular Atrophy". The aim of this study was to evaluate treatment patterns, SMA-related complications and services, and all-cause medical encounters of patients with SMA receiving multiple DMTs in the real world. The DMTs included onasemnogene abeparvovec-xioi (OA), nusinersen, and risdiplam. This study was conducted...
What is the current status of trial NCT07403214?
This trial is currently completed. The enrollment target is 4,805 participants. The study started on 2025-06-04. Estimated completion is 2025-06-30.
Who is sponsoring clinical trial NCT07403214?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01719055 · 4,800 participants
RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain
- NCT05485675 · 4,800 participants · NA
Stand & Move at Work II: Effectiveness and Implementation of a Worksite Wellness Program
- NCT06307652 · 4,800 participants · Phase 3
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
- NCT05252754 · 4,874 participants · Phase 3
Rectal Indomethacin and Oral Tacrolimus Versus Combination to Prevent Post-ERCP Pancreatitis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI